Additional file 4: of Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells

Figure S2. Dose-response curves of selected kinase inhibitors in parental and BRAFi-resistant IGR37 and 501Mel cells. Response to 3-fold serial dilutions of each kinase inhibitor was assessed 72 h after treatment by measuring cell viability in IGR37 (A) and 501Mel (B) cells. The values depicted in the different graphs indicate the half-maximal inhibitory concentrations (IC50) of inhibitors for which IC50 values could be determined (as explained in Methods). Values represent the mean of at least three biological replicates; one representative curve of at least 3 biological replicates is depicted. _XP: cells resistant to Vemurafenib (red), _GP: cells resistant to Dabrafenib (green). (PDF 304 kb